All In Biotech

Drug Trial Radar · NCT07220538

A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment

Pragmatic Open-label, Parallel-group Clinical Trial on the Effectiveness of Extract of Ginkgo Biloba Leaves Tablets as add-on to Standard of Care in Participants With Cognitive Impairment After an Acute Ischemic Stroke (GiCIIS)

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Nov 28, 2025

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
Collaborators
Beijing Tiantan Hospital
First posted
Oct 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if Extract of Ginkgo Biloba Leaves Tablets help improve thinking and memory in people aged 55 years and older who had an ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain). It will also look at how safe the Extract of Ginkgo Biloba Leaves Tablets are. The main questions it aims to answer are: * Do the Extract of Ginkgo Biloba Leaves Tablets help people with memory or thinking problems after an ischemic stroke? * What medical problems do people have when taking the Extract of Ginkgo Biloba Leaves Tablets ? Researchers will compare people who take the Extract of Ginkgo Biloba Leaves Tablets along with their usual post-stroke treatment to people who only receive their usual post-stroke treatment. Participants will: * Have had an ischemic stroke confirmed by MRI (Magnet Resonance Imaging, a magnetic scan that helps seeing inside the body in great detail) 7 to 14 days before joining the study * Take Extract of Ginkgo Biloba Leaves Tablets (240 mg per day) in addition to usual post-stroke treatment for 12 months, or receive only usual post-stroke treatment for 12 months * Be treated initially at hospitals across China * Visit the clinic 4, 26, and 52 weeks following the baseline for checkups and tests, and receive follow-up calls after 12 and 38 weeks.

Conditions

  • Ischemic Stroke Hospitalized
  • Impairment, Cognitive

Interventions

  • Extract of Ginkgo Biloba Leaves Tablets 240 mg (2 x 40 mg, t.i.d.)Drug

    3 x 2 film-coated tablets with 40 mg Extract of Ginkgo Biloba Leaves Tablets daily for 52 weeks plus standard of care in accordance with treatment guidelines

  • Standard of care (SoC) GroupOther

    Individualized therapy in accordance with treatment guideline from the Chinese Stroke Association

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Montreal Cognitive Assessment (MoCA) Total ScoreTime frame: From baseline to Week 26 (Visit 4) and Week 52 (Visit 6)
  2. Change in Cognitive Function Using Trail Making Test (TMT) Parts A and BTime frame: Change from baseline to Week 26 (Visit 4) and Week 52 (Visit 6)
  3. Change in Cognitive Processing Speed Using Symbol Digit Modalities Test (SDMT)Time frame: Change from baseline to Week 26 (Visit 4) and Week 52 (Visit 6)
  4. Change in Verbal Fluency Performance Using Verbal Fluency Test (VFT)Time frame: Change from baseline to Week 26 (Visit 4) and Week 52 (Visit 6)
  5. Change in Clinical Global Impression of Change Using ADCS-CGIC (Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change)Time frame: Change from baseline to Week 26 (Visit 4) and Week 52 (Visit 6)
  6. Change in Neurological Impairment Using National Institutes of Health Stroke Scale (NIHSS)Time frame: Change from Baseline to Week 4 (Visit 1), Week 26 (Visit 4) and Week 52 (Visit 6)
  7. Change in Neurological Impairment Using Modified Rankin Scale (mRS)Time frame: Change from Baseline to Week 4 (Visit 1), Week 26 (Visit 4) and Week 52 (Visit 6)
  8. Any new stroke event (ischemic stroke or hemorrhagic stroke) at Week 4, Week 12, Week 26, Week 38 and Week 52.Time frame: Week 4, Week 12, Week 26, Week 38 and Week 52

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • The People's Hospital of Anyang City

    Anyang, China

  • Baotou Central Hospital

    Baotou, China

  • Tiantan Hospital

    Beijing, China

  • Benxi Central Hospital

    Benxi, China

  • The First People's Hospital of Chenzhou

    Chenzhou, China

  • Affiliated Hospital of Chifeng University

    Chifeng, China

  • Affiliated Zhongshan Hospital of Dalian University

    Dalian, China

  • Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)

    Dalian, China

  • Dalian Lvshunkou District Traditional Chinese Medicine Hospital

    Dalian, China

  • Dalian University Affiliated Xinhua Hospital

    Dalian, China

  • The 2nd Affiliated Hospital of Harbin Medical University

    Harbin, China

  • Affiliated Hospital of Hebei University

    Hebei, China

  • The Second Hospital of Hebei Medical University

    Hebei, China

  • The Second Affiliated Hospital of Henan University of Science and Technology

    Henan, China

  • Huizhou First Hospital

    Huizhou, China

  • The First Affiliated Hospital of Jiamusi University

    Jiamusi, China

  • China-Japan Union Hospital of Jilin University

    Jilin City, China

  • Jiujiang No.1 People's Hospital

    Jiujiang, China

  • Liaocheng People´s Hospital

    Liaocheng, China

  • Liuzhou Workers´ Hospital

    Liuzhou, China

  • Luoyang Central Hospital

    Luoyang, China

  • Nanning First People's Hospital

    Nanning, China

  • Puyang Oilfield General Hospital

    Pujiang, China

  • Second Hospital of Shanxi Medical University

    Shanxi, China

  • Shanxi Cardiovascular Hospital

    Shanxi, China

  • The First People's Hospital Of Shenyang

    Shenyang, China

  • The People's Hospital of Liaoning Province

    Shenyang, China

  • Siping City Central People's Hospital

    Siping, China

  • Suining Central Hospital

    Suining, China

  • Weifang People´s Hospiztal

    Weifang, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, China

  • Yantaishan Hospital

    Yantai, China

  • Zhumadian Central Hospital

    Zhumadian, China

  • Zibo Municipal Hospital

    Zibo, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.